Advertisement

Clinical & Experimental Metastasis

, Volume 30, Issue 6, pp 711–721 | Cite as

Estradiol increases ER-negative breast cancer metastasis in an experimental model

  • Xujuan Yang
  • Aashvini Belosay
  • Mengyuan Du
  • Timothy M. Fan
  • Russell T. Turner
  • Urszula T. Iwaniec
  • William G. HelferichEmail author
Research Paper

Abstract

Breast cancer (BC) is the most common cancer affecting women in the United States and metastatic breast cancer is the leading cause of death. The role estradiol plays in ER-positive BC is well-documented, but the way it contributes to ER-negative BC remains unclear. In the present study, we utilized an experimental model of BC metastasis into lung by injecting ER-negative murine 4T1 cells into mice via the lateral tail vein. A 56 % metastasis occurrence rate following the injection of 5 × 103 cells was observed, thus this cell number was selected to study the potential stimulatory effect of estradiol on ER-negative BC metastasis. Female ovariectomized mice were randomized into estradiol and control groups with 16 mice per group, and estradiol pellets were implanted subcutaneously in the estradiol group. Results demonstrated that estradiol accelerated BC metastasis as indicated by bioluminescent imaging. In addition, estradiol enhanced metastatic tumor colony formation and increased the size of tumor nodules in the lungs, which were due, in part, to the increase in proliferative cells in the metastatic tumors. In vitro, estradiol increased the motility and invasion of 4T1 cells, and the stimulatory effect on cell motility was not blocked by ICI 182, 780, confirming that ER was not involved in the process. Results from the present study suggest that estradiol plays a role in ER-negative BC metastasis in whole animals.

Keywords

ER-negative breast cancer Metastasis Estradiol 4T1 cells 

Notes

Acknowledgement

This study was supported by the National Cancer Institute [CA77355 to W.G.H.]; the National Institute on Aging, the National Institute for Complementary and Alternative Medicine and the Office of Dietary Supplements, the Women’s Health Initiative [P01 AG024387 to W.G.H. and Y.H.J.]; and the National Institute for Complementary and Alternative Medicine, the Office of Dietary Supplements and the National Cancer Institute [P50AT006268 to W.G.H.]. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NICAM, ODS, NCI or the National Institutes of Health.

Conflict of interests

None declared.

References

  1. 1.
    Jemal A et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100(23):1672–1694PubMedCrossRefGoogle Scholar
  2. 2.
    Hagemeister FB Jr et al (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46(1):162–167PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A et al (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1):5–26PubMedCrossRefGoogle Scholar
  4. 4.
    Pavese JM, Farmer RL, Bergan RC (2010) Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 29(3):465–482PubMedCrossRefGoogle Scholar
  5. 5.
    Rosen PR et al (1989) A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7(3):355–366PubMedGoogle Scholar
  6. 6.
    Lee YT (1985) Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev 4(2):153–172PubMedCrossRefGoogle Scholar
  7. 7.
    Horwitz KB (2008) The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22(12):2743–2750PubMedCrossRefGoogle Scholar
  8. 8.
    Ma H et al (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8(4):R43PubMedCrossRefGoogle Scholar
  9. 9.
    Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRefGoogle Scholar
  10. 10.
    Kaaks R et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071–1082PubMedCrossRefGoogle Scholar
  11. 11.
    Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12(1):10–19PubMedCrossRefGoogle Scholar
  12. 12.
    Skliris GP et al (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109(1–2):1–10PubMedCrossRefGoogle Scholar
  13. 13.
    Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer–onlooker, passive player, or active protector? Steroids 73(11):1039–1051PubMedCrossRefGoogle Scholar
  14. 14.
    Omoto Y et al (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011–5020PubMedCrossRefGoogle Scholar
  15. 15.
    Buteau-Lozano H et al (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17):4977–4984PubMedGoogle Scholar
  16. 16.
    Chang EC et al (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831–4842PubMedCrossRefGoogle Scholar
  17. 17.
    Matthews J et al (2006) Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20(3):534–543PubMedCrossRefGoogle Scholar
  18. 18.
    Roger P et al (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537–2541PubMedGoogle Scholar
  19. 19.
    Leygue E et al (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58(15):3197–3201PubMedGoogle Scholar
  20. 20.
    Jarvinen TA et al (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156(1):29–35PubMedCrossRefGoogle Scholar
  21. 21.
    Fuqua SA et al (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10):2434–2439PubMedGoogle Scholar
  22. 22.
    O’Neill PA et al (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702PubMedGoogle Scholar
  23. 23.
    Platet N et al (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1):55–67PubMedCrossRefGoogle Scholar
  24. 24.
    Neven P et al (2002) Endocrine treatment and prevention of breast and gynaecological cancers. Eur J Cancer 38(Suppl 6):S1–S11PubMedCrossRefGoogle Scholar
  25. 25.
    Vergote I et al (2000) The oestrogen receptor and its selective modulators in gynaecological and breast cancer. Eur J Cancer 36(Suppl 4):S1–S9PubMedCrossRefGoogle Scholar
  26. 26.
    Hartman J, Strom A, Gustafsson JA (2009) Estrogen receptor beta in breast cancer–diagnostic and therapeutic implications. Steroids 74(8):635–641PubMedCrossRefGoogle Scholar
  27. 27.
    Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases–a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396(1):63–66PubMedCrossRefGoogle Scholar
  28. 28.
    Yue W et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757PubMedCrossRefGoogle Scholar
  29. 29.
    Acconcia F, Kumar R (2006) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238(1):1–14PubMedCrossRefGoogle Scholar
  30. 30.
    Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833–842PubMedCrossRefGoogle Scholar
  31. 31.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8784):1–15Google Scholar
  32. 32.
    Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85Google Scholar
  33. 33.
    Gupta PB et al (2007) Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67(5):2062–2071PubMedCrossRefGoogle Scholar
  34. 34.
    Banka CL et al (2006) Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 66(7):3667–3672PubMedCrossRefGoogle Scholar
  35. 35.
    Reeves PG, Nielsen FH, Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123(11):1939–1951PubMedGoogle Scholar
  36. 36.
    Miller FR (1983) Tumor subpopulation interactions in metastasis. Invasion Metastasis 3(4):234–242PubMedGoogle Scholar
  37. 37.
    Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3(1):22–31PubMedGoogle Scholar
  38. 38.
    Hong X et al (2009) EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Sci 100(5):961–969PubMedCrossRefGoogle Scholar
  39. 39.
    Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399–1405PubMedGoogle Scholar
  40. 40.
    Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58(7):1486–1493PubMedGoogle Scholar
  41. 41.
    Pulaski, B.A. and S. Ostrand-Rosenberg, Mouse 4T1 breast tumor model. Curr Protoc Immunol, 2001. Chapter 20: p. Unit-Uni2Google Scholar
  42. 42.
    Adams LS et al (2010) Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res 70(9):3594–3605PubMedCrossRefGoogle Scholar
  43. 43.
    Valster A et al (2005) Cell migration and invasion assays. Methods 37(2):208–215PubMedCrossRefGoogle Scholar
  44. 44.
    Ju YH et al (2001) Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 131(11):2957–2962PubMedGoogle Scholar
  45. 45.
    Ju YH et al (2006) Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 27(6):1292–1299PubMedCrossRefGoogle Scholar
  46. 46.
    Hiraga T et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559–4567PubMedCrossRefGoogle Scholar
  47. 47.
    Muller A et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56PubMedCrossRefGoogle Scholar
  48. 48.
    Ju YH et al (2006) Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 27(4):856–863PubMedCrossRefGoogle Scholar
  49. 49.
    Pike MC et al (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35PubMedGoogle Scholar
  50. 50.
    Gottardis MM, Robinson SP, Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30(1–6):311–314PubMedCrossRefGoogle Scholar
  51. 51.
    Alliende ME (2002) Mean versus individual hormonal profiles in the menstrual cycle. Fertil Steril 78(1):90–95PubMedCrossRefGoogle Scholar
  52. 52.
    Kaaks R et al (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755–765PubMedCrossRefGoogle Scholar
  53. 53.
    Bockhorn M, Jain RK, Munn LL (2007) Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8(5):444–448PubMedCrossRefGoogle Scholar
  54. 54.
    Nogawa M et al (2005) Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217(2):243–253PubMedCrossRefGoogle Scholar
  55. 55.
    Uneda S et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125(6):1446–1453PubMedCrossRefGoogle Scholar
  56. 56.
    Oviedo PJ et al (2011) Estradiol induces endothelial cell migration and proliferation through estrogen receptor-enhanced RhoA/ROCK pathway. Mol Cell Endocrinol 335(2):96–103PubMedCrossRefGoogle Scholar
  57. 57.
    Acconcia F, Barnes CJ, Kumar R (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147(3):1203–1212PubMedCrossRefGoogle Scholar
  58. 58.
    Sanchez AM et al (2010) Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24(11):2114–2125PubMedCrossRefGoogle Scholar
  59. 59.
    Kedrin D et al (2007) Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 12(2–3):143–152PubMedCrossRefGoogle Scholar
  60. 60.
    Giretti MS et al (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3(5):e2238PubMedCrossRefGoogle Scholar
  61. 61.
    Zheng S et al (2011) 17beta-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS ONE 6(7):e22439PubMedCrossRefGoogle Scholar
  62. 62.
    Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17):1260–1270PubMedCrossRefGoogle Scholar
  63. 63.
    Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253–261PubMedCrossRefGoogle Scholar
  64. 64.
    Migliaccio A et al (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15(6):1292–1300PubMedGoogle Scholar
  65. 65.
    Zhang Z et al (2004) The role of adapter protein Shc in estrogen non-genomic action. Steroids 69(8–9):523–529PubMedCrossRefGoogle Scholar
  66. 66.
    Song RX et al (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 101(7):2076–2081PubMedCrossRefGoogle Scholar
  67. 67.
    Yang Z, Barnes CJ, Kumar R (2004) Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10(11):3621–3628PubMedCrossRefGoogle Scholar
  68. 68.
    Restall C et al (2009) A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. Int J Cancer 125(2):483–487PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Xujuan Yang
    • 1
  • Aashvini Belosay
    • 1
  • Mengyuan Du
    • 1
  • Timothy M. Fan
    • 2
  • Russell T. Turner
    • 3
  • Urszula T. Iwaniec
    • 3
  • William G. Helferich
    • 1
    Email author
  1. 1.Department of Food Science and Human NutritionUniversity of Illinois at Urbana-ChampaignUrbanaUSA
  2. 2.Department of Veterinary Clinical MedicineUniversity of Illinois at Urbana-ChampaignUrbanaUSA
  3. 3.Skeletal Biology LaboratorySchool of Biological and Population Health Sciences, Oregon State UniversityCorvallisUSA

Personalised recommendations